

# **Document made available under the Patent Cooperation Treaty (PCT)**

International application number: PCT/EP05/002809

International filing date: 16 March 2005 (16.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US

Number: 60/557,358

Filing date: 29 March 2004 (29.03.2004)


Date of receipt at the International Bureau: 13 April 2005 (13.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

PA 1282371



**THE UNITED STATES OF AMERICA**

**TO ALL TO WHOM THESE PRESENTS SHALL COME:**

**UNITED STATES DEPARTMENT OF COMMERCE**

**United States Patent and Trademark Office**

**February 09, 2005**

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE UNDER 35 USC 111.**


**APPLICATION NUMBER: 60/557,358**

**FILING DATE: March 29, 2004**

**By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS**



**M. SIAS  
Certifying Officer**



Docket Number	4-33687P2
<b>FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10</b>	
EV443788572US Express Mail Label Number	March 29, 2004 Date of Deposit

Address to: MS: Provisional Patent Application  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

22151 U.S.PTO  
60/557358  
032904



### PATENT COVER SHEET FOR PROVISIONAL APPLICATION

Transmitted herewith for filing under 37 CFR §1.53(c) is the PROVISIONAL APPLICATION for patent of

INVENTOR(S)		
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
David Louis Steven	Feldman Zelenkofske	Teaneck, New Jersey East Hanover, New Jersey
TITLE OF THE INVENTION (280 characters max)		
USE OF ORGANIC COMPOUNDS		

#### CORRESPONDENCE ADDRESS

Direct all correspondence to the address associated with Customer No. 001095, which is currently:

Thomas Hoxie  
Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 430  
East Hanover, NJ 07836-1080

#### ENCLOSED APPLICATION PARTS (check all that apply)

Specification (Including Any Claims and Abstract) - 25 pages  
 Drawings - sheets  
 Other (specify): Application Data Sheet

#### METHOD OF PAYMENT

The Commissioner is hereby authorized to charge filing fee and any additional fees required to Deposit Account Number: 19-0134 in the name of Novartis.

PROVISIONAL FILING FEE AMOUNT: \$ 160

U.S. Government agency and contract number: (if the invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.)

Respectfully submitted,

  
\_\_\_\_\_  
Gregory D. Ferrero  
Attorney for Applicants  
Reg. No. 36,134  
Tel. No. (892) 778-7831

Date: March 29, 2004

**USE OF ORGANIC COMPOUNDS**

Aliskiren inhibits the action of the natural enzyme renin. The latter passes from the kidneys into the blood where it effects the cleavage of angiotensinogen, releasing the decapeptide angiotensin I which is then cleaved in the lungs, the kidneys and other organs to form the octapeptide angiotensinogen II. The octapeptide increases blood pressure both directly by arterial vasoconstriction and indirectly by liberating from the adrenal glands the sodium-ion-retaining hormone aldosterone, accompanied by an increase in extracellular fluid volume. That increase can be attributed to the action of aldosterone. Inhibitors of the enzymatic activity of renin bring about a reduction in the formation of angiotensin I. As a result a proportionately smaller amount of angiotensin II is produced. The reduced concentration of that active peptide hormone is the direct cause of, e.g., the hypotensive effect of renin inhibitors.

Further evaluations revealed that renin inhibitors can be used for a broader range of therapeutic indications.

The invention relates to a method for the prevention of, delay progression to overt or treatment of a condition or disease selected from:

- (a) diabetes type 2 (associated with or without hypertension). For an example of a model useful to demonstrate the treatment of renal protection in type 2 diabetes with HT, see Kelly et al., *Kid Int*, Vol. 54, pp. 343-352 (1998); and for renal protection DM w/o HT: db/db mice, see Ziyadeh et al., *Proc Natl Acad Sci U S A*, Vol. 97, No. 14, pp. 8015-8020 (2000);
- (b) severe hypertension, pulmonary hypertension (PH), malignant hypertension, isolated hypertension and familial dyslipidemic hypertension. For an example of a model useful to demonstrate the treatment of severe hypertension and malignant hypertension, see Park et al., *Am J Hypertens*, Vol. 15, No. 1, Part 1, pp. 78-84 (2002); and for PH, see Jones et al., *Am J Physiol Heart Circ Physiol* (2004);
- (c) endothelial dysfunction (with or without hypertension). For an example of a model useful to demonstrate the treatment of endothelial dysfunction (with or without hypertension), see Shinozaki et al., *Diabetes*, Vol. 48, pp. 2437-2445 (1999);

- (d) survival post-myocardial infarction (MI); increase of formation of collagen and other extracellular matrix proteins and coarctation of aorta. For an example of a model useful to demonstrate the treatment of survival post-MI and increase of formation of collagen, see Villarreal et al., *Circulation*, Vol. 108, No. 12, pp. 1487-1492 (2003);
- (e) restenosis after stenting. For an example of a model useful to demonstrate the treatment of angioplasty, see Huang et al., *Heart*, Vol. 90, pp. 195-199 (2004);
- (f) peripheral vascular disease (PWD) including peripheral artery disease (PAD) and peripheral venous disorders;
- (g) coronary arterial disease (CAD). For an example of a model useful to demonstrate the treatment of CAD, see Gerrity et al., *Diabetes*, Vol. 50, No. 7, pp. 1654-1655 (2001);
- (h) morbidity and mortality;
- (i) cerebrovascular diseases. For an example of a model useful to demonstrate the treatment of this indication, see Park et al. (2002), *supra*;
- (j) metabolic disorder (Syndrome X). See Wang et al., *Circulation*, Vol. 107, pp. 1923-1929 (2003);
- (k) atrial fibrillation (AF);
- (l) renoprotection and reduction of proteinuria;
- (m) renal failure, e.g., chronic renal failure;
- (n) glomerulonephritis (may be associated with the nephrotic syndrome, a high blood pressure and a decreased renal function), focal, segmental glomerulonephritis and minimal change nephropathy;
- (o) nephrotic syndrome and renal fibrosis;
- (p) acute interstitial nephritis (AIN), acute tubular nephritis (ATN) and acute tubulo-interstitial nephritis;
- (q) PKD. See Martinez et al., *Am J Kidney Dis*, Vol. 29, pp. 435-444 (1997);
- (r) vascular inflammation;
- (s) rennin secreting tumors;
- (t) migraine headaches;
- (u) vasculitides; and
- (v) closure and restenosis of dialysis access grafts,

comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof.

A further object of the present invention is to provide therapeutic compositions and method that further aid in stabilizing plaques comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof. By plaque stabilization, it is meant the inhibition of plaque passing through a phase in which the lipid core has grown and the fibrous cap is very thin and vulnerable to rupture due to an increase in the density of macrophages.


In a preferred aspect of the present invention, there is provided a method for the prevention of, delay progression to overt to or treatment of a condition or disease selected from diabetes type 2 (associated with or without hypertension), isolated systolic hypertension, endothelial dysfunction (with or without hypertension), survival post-MI, restenosis after stenting, PVD, CAD, morbidity, mortality, cerebrovascular diseases, metabolic disorder (Syndrome X), renoprotection and vascular inflammation.

The prevention of, delay progression to overt to or treatment of a condition or disease which is different from category (b) as described hereinbefore or hereinafter is understood to be effected in patients without or with hypertension.

A rennin inhibitor is a drug that pharmacologically effectively inhibits the enzyme renin resulting in prevention of, delay progression of and treatment of conditions and diseases associated with the inhibition of renin, especially such conditions and diseases as specified hereinbefore and hereinafter.

Renin inhibitors comprise, e.g., peptidic and, preferably, non-peptidic renin inhibitors.


A non-peptidic renin inhibitor is, e.g., ditekiren, terlakiren, zankiren, SPP-100 or a compound of formula (I)




or, in each case, a pharmaceutically acceptable salt thereof.


The renin inhibitor of formula (I), chemically defined as 2(S),4(S),5(S),7(S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamide, is specifically disclosed in EP 678503 A. Especially preferred is the hemi-fumarate salt thereof.

Non-peptidic renin inhibitor comprise those that are disclosed in WO 97/09311, especially corresponding renin inhibitors as disclosed in the claims and working examples, especially SPP100 of the formula



especially and of RO 66-1132 and RO-66-1168 of formula





respectively, WO 04/002957, especially those renin inhibitors as disclosed in the working examples and claims. The corresponding subject matter of said WO applications is herein incorporated by reference into the present invention.

The structure of the active agents identified hereinbefore or hereinafter by generic or tradenames may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g., Patent Focus, e.g. IMS Life Cycle - IMS World Publications. The corresponding content thereof is hereby incorporated by reference. Any person skilled in the art is fully enabled to identify the active agents and, based on these references, likewise enabled to manufacture and test the pharmaceutical indications and properties in standard test models, both *in vitro* and *in vivo*.

#### DEFINITIONS

Type 2 diabetes mellitus including type 2 diabetes mellitus associated with hypertension is a disease in which the pancreas does not secrete sufficient insulin due to an impairment of pancreatic beta-cell function and/or in which there is to insensitivity to produced insulin (insulin resistance). Typically, the fasting plasma glucose is less than 126 mg/dL, while pre-diabetes is, e.g., a condition which is characterized by one of following conditions: impaired fasting glucose (110-125 mg/dL) and impaired glucose tolerance (fasting glucose levels less than 126 mg/dL and post-prandial glucose level between 140 mg/dL and 199 mg/dL). Type 2 diabetes mellitus can be associated with or without hypertension. Diabetes mellitus occurs frequently, e.g., in African American, Latino/Hispanic American, Native American, Native American, Asian American and Pacific Islanders. Markers of insulin resistance include HbA1C, HOMA IR, measuring collagen fragments, TGF- $\beta$  in urine, PAI-1 and prorenin.

Severe hypertension is characterized by a systolic blood pressure of  $\geq 180$  mm Hg and a diastolic blood pressure of  $\geq 110$  mm Hg.

Pulmonary hypertension (PH) is a blood vessel disorder of the lung in which the pressure in the pulmonary artery rises above normal level of  $\leq 25/10$  (especially primary and secondary PH), e.g., because the small vessels that supply blood to the lungs constrict or tighten up. According to the WHO, PH may be divided into five categories: pulmonary arterial hypertension (PAH), a PH occurring in the absence of a known cause is referred to as primary pulmonary hypertension, while secondary PH is caused by a condition selected, e.g., from emphysema; bronchitis; collagen vascular diseases, such as scleroderma, Crest syndrome or systemic lupus erythematosus (SLE); PH associated with disorders of the respiratory system; PH due to chronic thrombotic or embolic disease; PH due to disorders directly affecting the pulmonary blood vessels; and pulmonary venous hypertension (PVH).

Malignant hypertension is usually defined as very high blood pressure with swelling of the optic nerve behind the eye, called papilledema (grade IV Keith-Wagner hypertensive retinopathy). This also includes malignant HTN of childhood.

Isolated systolic hypertension is characterized by a systolic blood pressure of  $\geq 140$  mm Hg and a diastolic blood pressure of  $< 90$  mm Hg.

Familial dyslipidemic hypertension is characterized by mixed dyslipidemic disorders. Biomarkers include oxidized LDL, HDL, glutathione and homocysteine LPa.

Renovascular hypertension (renal artery stenosis) is a condition where the narrowing of the renal artery is significant which leads to an increase of the blood pressure resulting from signals sent out by the kidneys. Biomarkers include rennin, PRA and prorenin.

Endothelial dysfunction with or without hypertension is a condition in which normal dilation of blood vessels is impaired due to lack of endothelium-derived vasodilators. Biomarkers include CRP, IL6, ET1, BIG ET1, VCAM and ICAM. Survival post-MI biomarkers include BNP and procollagen factors.

Organ/renal/cardiac fibrosis is defined as abnormally high accumulation of collagen and other extracellular matrix proteins due to the enhanced production or decreased degradation of these proteins. Biomarkers include BNP, procollagen factors, LVH, AGE RAGE and CAGE.

Coarctation of aorta is an area of localized narrowing of the large artery (aorta). The narrowing may be caused by a "shelf" tissue inside the blood vessel which reduces its area. Alternatively, it may be caused by underdevelopment of portion of the aorta itself which cases a longer area of reduced diameter.

Restenosis after percutaneous transluminal angioplasty is defined as the closure of an artery following a procedure to open said artery that is fully or partially-blocked by the accumulation of plaque or other disease. Biomarkers include coronary flow reserve.

Peripheral vascular disease (PWD) refers to the damage or dysfunction of peripheral blood vessels. There are two types of peripheral vascular diseases: peripheral arterial disease (PAD) which refers to diseased peripheral arteries and peripheral venous disorders, which can be measured by an ankle brachial index.

PAD is a condition that progressively hardens and narrows arteries due to a gradual buildup of plaque and refers to conditions that effect the blood vessels, such as arteries, veins and capillaries, of the body outside the heart. This is also known as peripheral venous disorder.

Thrombophlebitis is a condition where an obstructing blood clot has been formed causing the surrounding veins to become inflamed.

Varicose veins is a condition where abnormally widened veins are swollen, dark and twisted or contorted. This usually occurs in the legs.

Chronic venous insufficiency is an advanced stage of leg vein disease in which the veins become incompetent causing blood to pool in the legs and feed and sometimes to leak backwards.

Coronary arterial disease (CAD) is a condition that progressively hardens and narrows arteries due to a gradual buildup of plaque and refers to conditions that effect the blood vessels such as arteries within the heart. CAD is peculiar form of atherosclerosis that occurs in the three small arteries supplying the heart muscle with oxygen-rich blood. Biomarkers include CPK and Troponin.

Cerebrovascular diseases comprise stroke conditions, such as embolic and thrombotic stroke; large vessel thrombosis and small vessel disease; and hemorrhagic stroke.

Embolic stroke is characterized by the formation of blood clots, e.g., in the heart, when clots travel down through the bloodstream in the brain. This may lead to a blockade of small blood vessels and causing a stroke.

Thrombotic stroke is a condition where the blood flow is impaired because of a blockade to one or more of the arteries supplying blood to the brain. This process normally leads to thrombosis causing thrombotic strokes. Biomarkers include PAI 1, TPA and platelet function.

Metabolic disorder (Syndrome X): Among various definitions of metabolic syndrome that are known three of them are of particular relevance. Metabolic syndrome is characterized by three or more of the following criteria:

1. Abdominal obesity: waist circumference >102 cm in men and >88 cm in women
2. Hypertriglyceridemia: >150 mg/dL (1.695 mmol/L)
3. Low HDL cholesterol: <40 mg/dL (1.036 mmol/L) in men and <50 mg/dL (1.295 mmol/L) in women
4. High blood pressure: >130/85 mm Hg
5. High-fasting glucose: >110 mg/dL (>6.1 mmol/L)

Metabolic syndrome can also be characterized by three or more of the following criteria: triglycerides >150 mg/dL, systolic blood pressure (BP) ≥130 mm Hg or diastolic BP ≥85 mm Hg or on anti-hypertensive treatment, high-density lipoprotein cholesterol <40 mg/dL, fasting blood sugar (FBS) >110 mg/dL, and a body mass index (BMI) >28.8 kg/m<sup>2</sup>.

Metabolic syndrome can also be characterized by diabetes, impaired glucose tolerance, impaired fasting glucose, or insulin resistance plus two or more of the following abnormalities:

1. High blood pressure: ≥160/90 mm Hg
2. Hyperlipidemia: triglyceride concentration ≥150 mg/dL (1.695 mmol/L) and/or HDL cholesterol <35 mg/dL (0.9 mmol/L) in men and <39 mg/dL (1.0 mmol/L) in women
3. Central obesity: waist-to-hip ratio of >0.90 in men or >0.85 in women and/or BMI >30 kg/m<sup>2</sup>
4. Microalbuminuria: urinary albumin excretion rate ≥20 µg/min. or an albumin-to-creatinine ratio ≥20 mg/g. Biomarkers include proteinuria, TGF-β, TNF-α and adiponectin.

Biomarkers include LDL, HDL and all the endothelial dysfunction markers.

Atrial fibrillation (AF) is a type of irregular or "racing" heartbeat that may cause blood to collect in the heart and potentially form a clot which may travel to the brain and can cause a stroke.

Organ protection is the prevention of loss of function of the restoration of impaired function of a bodily organ.

Renoprotection is reduction of proteinuria. Biomarkers include, collagen fragments and TGF- $\beta$  in urine.

Renal failure, e.g., chronic renal failure; is characterized, e.g., by proteinuria and/or slight elevation of plasma creatinine concentration (106-177 mmol/L corresponding to 1.2-2.0 mg/dL).

Glomerulonephritis may be associated with the nephrotic syndrome, a high blood pressure and a decreased renal function; focal, segmental glomerulonephritis; minimal change nephropathy, Lupus nephritis, post-streptococcal GN and IgA nephropathy.

Nephrotic syndrome is a compilation of conditions including massive proteinuria, edema and CNS irregularities. Biomarkers include urinary protein excretion.

Plaque stabilization means rendering a plaque less dangerous by preventing, fibrous cap thinning/rupture, smooth muscle cell loss and inflammatory cell accumulation.

Renal fibrosis is an abnormal accumulation of collagen and other extracellular matrix proteins, leading to loss of renal function. Biomarkers include collagen fragments and TGF- $\beta$  in urine.

End-stage renal disease (ESRD) is loss of renal function to the extent that dialysis or renal replacement is needed. Biomarkers include glomerular filtration rate and creatinine clearance.

Polycystic kidney disease (PKD) is a genetic disorder characterized by the growth of numerous cysts in the kidney. PKD cysts can slowly reduce much of the mass of kidneys reducing kidney function and leading to kidney failure. PKD may be classified as two major inherited forms of PKD which are autosomal dominant PKD and autosomal recessive PKD, while the non-inherited PKD may be called acquired cystic kidney disease. Biomarkers include reduction of renal cysts by non-invasive imaging.

Obesity is an overweight condition defined by BMI of >30.

The term "prevention" means prophylactic administration to healthy patients to prevent the outbreak of the conditions mentioned herein. Moreover, the term "prevention" means prophylactic administration to patients being in a pre-stage of the conditions, to be treated.

The term "delay progression to overt to", as used herein, means administration to patients being in a pre-stage of the condition to be treated in which patients a pre-form of the corresponding condition is diagnosed.

The term "treatment" is understood the management and care of a patient for the purpose of combating the disease, condition or disorder.

An "effective amount" shall mean that amount of compound that will elicit the biological or medical response of a tissue, system or animal (including man) that is being sought by a researcher or clinician.

The terms "warm-blooded animal or patient" are used interchangeably herein and include, but are not limited to, humans, dogs, cats, horses, pigs, cows, monkeys, rabbits, mice and laboratory animals. The preferred mammals are humans.

A "pharmaceutically acceptable salt" refers to a non-toxic salt commonly used in the pharmaceutical industry, which are prepared by methods well-known in the art.

Surprisingly, the present invention has a longer duration of action than ACE or ARB's while maintaining the same efficacy. Moreover, renin is a direct vasodilator and has direct profibrotic effects. By blocking renin activity one would expect anti-inflammatory and antifibrotic effects in addition to what is seen with ACE and ARBs due to additive effect of RI on ANGII and rennin blockade. Further, renin blockade effects ANG4 and ANG1-7. Ang 1-7 is suspected to have beneficial effects which effects inflammation, thrombosis, fibrosis and cell proliferation.

All the more surprising is the experimental finding that the combined administration of the renin inhibitor of formula (I) or a salt thereof with a therapeutic agent selected from the group consisting of (i)-(xiv), as defined below, results not only in a beneficial, especially a synergistic, therapeutic effect or a potentiation of at least one of the combination partners, but also in additional benefits resulting from the combined treatment and further surprising

beneficial effects compared to a monotherapy applying only one of the pharmaceutically active compounds used in the combinations disclosed herein.

The invention similarly relates to combinations, e.g., pharmaceutical combinations, containing a renin inhibitor of the present invention or, in each case, a pharmaceutically acceptable salt thereof in combination with at least one active principle, or in each case, a pharmaceutically acceptable salt thereof.

The combination may be made, for example, with the following compositions, selected from the group consisting of:

- (i) an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof;
- (ii) ACE inhibitor or a pharmaceutically acceptable salt thereof;
- (iii) calcium channel blocker or a pharmaceutically acceptable salt thereof;
- (iv) HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof;
- (v) aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof;
- (vi) aldosterone antagonist or a pharmaceutically acceptable salt thereof;
- (vii) dual ACE/NEP inhibitor or a pharmaceutically acceptable salt thereof;
- (viii) beta-blocker or a pharmaceutically acceptable salt thereof;
- (ix) endothelin (ET) antagonist or a pharmaceutically acceptable salt thereof;
- (x) diuretic or a pharmaceutically acceptable salt thereof;
- (xi) oral hypoglycaemic agent or a pharmaceutically acceptable salt thereof;
- (xii) a Mrp2 inhibitor;
- (xiii) furosemide or a pharmaceutically acceptable salt thereof; and
- (xiv) Gleevec or a pharmaceutically acceptable salt thereof.

The combination according to the present invention can be used, for example, for the prevention of, delay progression to overt to or treatment of a condition or disease selected from:

- (a) diabetes type 2 (associated with or without hypertension);
- (b) severe hypertension, PH, malignant hypertension, isolated systolic hypertension and familial dyslipidemic hypertension;
- (c) endothelial dysfunction (with or without hypertension);
- (d) survival post-MI, increase of formation of collagen and coarctation of aorta;
- (e) restenosis after percutaneous transluminal angioplasty
- (f) PVD, including PAD and peripheral venous disorders;
- (g) CAD;

- (h) morbidity and mortality;
- (i) cerebrovascular diseases;
- (j) metabolic disorder (Syndrome X);
- (k) AF;
- (l) organ protection;
- (m) renoprotection;
- (n) renal failure, e.g., chronic renal failure;
- (o) glomerulonephritis (may be associated with the nephritic syndrome, a high blood pressure and a decreased renal function), focal, segmental glomerulonephritis and minimal change nephropathy;
- (p) nephrotic syndrome and renal fibrosis;
- (q) AIN, ATN and acute tubulo-interstitial nephritis;
- (r) ESRD;
- (s) PKD;
- (t) vascular inflammation;
- (u) obesity;
- (v) migraine headaches
- (w) renin secreting tumors; and
- (x) vasculitides.


The combination according to the present invention may be used in a method of stabilizing plaques comprising administering to a warm-blooded animal an effective amount of a combination of the invention or pharmaceutically acceptable salts thereof.

The combination according to the present invention comprising a renin inhibitor or a pharmaceutically acceptable salt thereof can be administered by various routes of administration. Each agent can be tested over a wide-range of dosages to determine the optimal drug level for each agent in combination to elicit the maximal response. For these studies, it is preferred to use treatment groups consisting of at least 6 animals per group. Each study is best performed in which the effects of the combination treatment group are determined at the same time as the individual components are evaluated. Although drug effects may be observed with acute administration (such as 1 day), it is preferable to observe responses in a chronic setting as shown below in which experiments were done over a two to three week observation period. The long-term study is of sufficient duration to allow for the full development of compensatory responses to occur and therefore, the


observed effect will most likely depict the actual responses of the test system representing sustained or persistent effects.

AT<sub>1</sub>-receptor antagonists (also called angiotensin II receptor antagonists) are understood to be those active ingredients that bind to the AT<sub>1</sub>-receptor subtype of angiotensin II receptor but do not result in activation of the receptor. As a consequence of the inhibition of the AT<sub>1</sub>-receptor, these antagonists can, e.g., be employed as anti-hypertensives or for treating congestive heart failure.


The class of AT<sub>1</sub>-receptor antagonists comprises compounds having differing structural features, essentially preferred are the non-peptidic ones. For example, mention may be made of the compounds that are selected from the group consisting of valsartan (cf. EP 443983), losartan (cf. EP253310), candesartan (cf. 459136), eprosartan (cf. EP 403159), irbesartan (cf. EP454511), olmesartan (cf. EP 503785), tasosartan (cf. EP539086), telmisartan (cf. EP 522314), the compound with the designation E-1477 of the formula



the compound with the designation SC-52458 of the formula



and the compound with the designation ZD-8731 of the formula



or, in each case, a pharmaceutically acceptable salt thereof.

Preferred AT<sub>1</sub>-receptor antagonist are those agents that have been marketed, most preferred is valsartan or a pharmaceutically acceptable salt thereof.

HMG-Co-A reductase inhibitors (also called β-hydroxy-β-methylglutaryl-co-enzyme-A reductase inhibitors) are understood to be those active agents that may be used to lower the lipid levels including cholesterol in blood.

The class of HMG-Co-A reductase inhibitors comprises compounds having differing structural features. For example, mention may be made of the compounds that are selected from the group consisting of atorvastatin, cerivastatin, compactin, dalcavastatin, dihydrocompactin, fluindostatin, fluvastatin, lovastatin, pitavastatin, mevastatin, pravastatin, rivastatin, simvastatin, rosuvastatin and velostatin, or, in each case, a pharmaceutically acceptable salt thereof.

Preferred HMG-Co-A reductase inhibitors are those agents which have been marketed, most preferred is fluvastatin and pitavastatin or, in each case, a pharmaceutically acceptable salt thereof.

The interruption of the enzymatic degradation of angiotensin I to angiotensin II with so-called ACE inhibitors is a successful variant for the regulation of blood pressure and thus also makes available a therapeutic method for the treatment of congestive heart failure.

The class of ACE inhibitors comprises compounds having differing structural features. For example, mention may be made of the compounds which are selected from the group

consisting alacepril, benazepril, benazeprilat, captopril, ceronapril, cilazapril, delapril, enalapril, enaprilat, fosinopril, imidapril, lisinopril, moveltopril, perindopril, quinapril, ramipril, spirapril, temocapril and trandolapril, or, in each case, a pharmaceutically acceptable salt thereof.

Preferred ACE inhibitors are those agents that have been marketed, most preferred are benazepril and enalapril.

The class of CCBs essentially comprises dihydropyridines (DHPs) and non-DHPs, such as diltiazem-type and verapamil-type CCBs.

A CCB useful in said combination is preferably a DHP representative selected from the group consisting of amlodipine, felodipine, ryosidine, isradipine, lacidipine, nicardipine, nifedipine, nulgipine, niludipine, nimodipine, nisoldipine, nitrendipine and nivaldipine, and is preferably a non-DHP representative selected from the group consisting of flunarizine, prenylamine, diltiazem, fendiline, gallopamil, mibepradil, aniparmil, tiapañnil and verapamil, and in each case, a pharmaceutically acceptable salt thereof. All these CCBs are therapeutically used, e.g., as anti-hypertensive, anti-angina pectoris or anti-arrhythmic drugs.


Preferred CCBs comprise amlodipine, diltiazem, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine and verapamil, or, e.g., dependent on the specific CCB, a pharmaceutically acceptable salt thereof. Especially preferred as DHP is amlodipine or a pharmaceutically acceptable salt, especially the besylate, thereof. An especially preferred representative of non-DHPs is verapamil or a pharmaceutically acceptable salt, especially the hydrochloride, thereof.

Aldosterone synthase is an enzyme that converts corticosterone to aldosterone by hydroxylating corticosterone to form 18-OH-corticosterone and 18-OH-corticosterone to aldosterone. The class of aldosterone synthase inhibitors is known to be applied for the treatment of hypertension and primary aldosteronism comprises both steroid and non-steroidal aldosterone synthase inhibitors, the later being most preferred.


Preference is given to commercially-available aldosterone synthase inhibitors or those aldosterone synthase inhibitors that have been approved by the health authorities.

The class of aldosterone synthase inhibitors comprises compounds having differing structural features. For example, mention may be made of the compounds which are selected from the group consisting of the non-steroidal aromatase inhibitors anastrozole, fadrozole (including the (+)-enantiomer thereof), as well as the steroidal aromatase inhibitor exemestane, or, in each case where applicable, a pharmaceutically acceptable salt thereof.

The most preferred non-steroidal aldosterone synthase inhibitor is the (+)-enantiomer of the (U.S. Patent Nos. 4,617,307 and 4,889,861), or a pharmaceutically acceptable salt thereof, e.g., the hydrochloride of fadrozole of formula



A preferred steroidal aldosterone antagonist is eplerenone of the formula



or spironolactone.

A preferred dual ACE/NEP inhibitor is, e.g., omapatrilate (cf. EP 629627), fasidotril or fasidotrilate, or Z 13752A (cf. WO 97/24342) or, if appropriate, a pharmaceutically acceptable salt thereof.

Beta-blockers suitable for use in the present invention include beta-adrenergic blocking agents (beta-blockers) which compete with epinephrine for beta-adrenergic receptors and interfere with the action of epinephrine. Preferably, the beta-blockers are selective for the beta-adrenergic receptor as compared to the alpha-adrenergic receptors, and so do not have a significant alpha-blocking effect. Suitable beta-blockers include compounds selected from acebutolol, atenolol, betaxolol, bisoprolol, carteolol, carvedilol, esmolol, labetalol,

metoprolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol and timolol. Where the beta-blocker is an acid or base or otherwise capable of forming pharmaceutically acceptable salts or prodrugs, these forms are considered to be encompassed herein, and it is understood that the compounds may be administered in free form or in the form of a pharmaceutically acceptable salt or a prodrug, such as a physiologically hydrolyzable and acceptable ester. For example, metoprolol is suitably administered as its tartrate salt, propranolol is suitably administered as the hydrochloride salt, and so forth.

ET is a highly-potent, vasoconstrictor peptide synthesized and released by the vascular endothelium. ET exists in three isoforms (ET-1, ET-2 and ET-3). ET shall mean any or all other isoforms of ET. Elevated levels of ET have been reported in plasma from patients with, e.g., essential hypertension. ET receptor antagonist can be used to inhibit the vasoconstrictive effects induced by ET.

A preferred ET antagonist is, e.g., bosentan (cf. EP 526708 A), enrasentan (cf. WO 94/25013), atrasentan (cf. WO 96/06095), especially atrasentan hydrochloride, darusentan (cf. EP 785926 A), BMS 193884 (cf. EP 702012 A), sitaxsentan (cf. U.S. Patent No. 5,594,021), especially sitaxsentan sodium, YM 598 (cf. EP 882719 A), S 0139 (cf. WO 97/27314), J 104132 (cf. EP 714897 A or WO 97/37665), furthermore, tezosentan (cf. WO 96/19459), or in each case, a pharmaceutically acceptable salt thereof.

A diuretic is, e.g., a thiazide derivative selected from the group consisting of chlorothiazide, hydrochlorothiazide, methylclothiazide, amiloride, triamterene and chlorothalidon. The most preferred is hydrochlorothiazide.

Preferably, the jointly therapeutically effective amounts of the active agents according to the combination of the present invention can be administered simultaneously or sequentially in any order, separately or in a fixed combination.

The pharmaceutical composition according to the present invention as described hereinbefore and hereinafter may be used for simultaneous use or sequential use in any order, for separate use or as a fixed combination.

The corresponding active ingredients or a pharmaceutically acceptable salts thereof may also be used in form of a solvate, such as a hydrate or including other solvents, used for crystallization.

The compounds to be combined can be present as pharmaceutically acceptable salts. If these compounds have, e.g., at least one basic center, they can form acid addition salts. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center. The compounds having an acid group, e.g., COOH, can also form salts with bases.

In a variation thereof, the present invention likewise relates to a "kit-of-parts", e.g., in the sense that the components to be combined according to the present invention can be dosed independently or by use of different fixed combinations with distinguished amounts of the components, i.e., simultaneously or at different time points. The parts of the kit of parts can then, e.g., be administered simultaneously or chronologically staggered, that is at different time points and with equal or different time intervals for any part of the kit of parts. Preferably, the time intervals are chosen such that the effect on the treated disease or condition in the combined use of the parts is larger than the effect that would be obtained by use of only any one of the components.

The invention furthermore relates to a commercial package comprising the combination according to the present invention together with instructions for simultaneous, separate or sequential use.

Dosaging may depend on various factors, such as mode of application, species, age and/or individual condition. For oral application, the doses to be administered daily are between 10 mg to 1 g.

The term "synergistic", as used herein, means that the effect achieved with the methods and compositions of the present invention is greater than the sum of the effects that result from individual methods and compositions comprising the active ingredients of this invention separately.

The person skilled in the pertinent art is fully enabled to select a relevant and standard animal test model to prove the hereinbefore and hereinafter indicated therapeutic indications and beneficial effects.

These pharmaceutical preparations are for enteral, such as oral, and also rectal or parenteral, administration to homeotherms, with the preparations comprising the pharmacological active compound either alone or together with customary pharmaceutical auxiliary substances. For example, the pharmaceutical preparations consist of from about

0.1-90%, preferably of from about 1% to about 80%, of the active compound. Pharmaceutical preparations for enteral or parenteral, and also for ocular, administration are, e.g., in unit dose forms, such as coated tablets, tablets, capsules or suppositories and also ampoules. These are prepared in a manner that is known *per se*, e.g., using conventional mixing, granulation, coating, solubilizing or lyophilizing processes. Thus, pharmaceutical preparations for oral use can be obtained by combining the active compound with solid excipients, if desired granulating a mixture which has been obtained, and, if required or necessary, processing the mixture or granulate into tablets or coated tablet cores after having added suitable auxiliary substances.

The dosage of the active compound can depend on a variety of factors, such as mode of administration, homeothermic species, age and/or individual condition.

Preferred dosages for the active ingredients of the pharmaceutical combination according to the present invention are therapeutically effective dosages, especially those which are commercially-available.

Normally, in the case of oral administration, an approximate daily dose of from about 1 mg to about 360 mg is to be estimated, e.g., for a patient of approximately 75 kg in weight.

The dosage of the active compound can depend on a variety of factors, such as mode of administration, homeothermic species, age and/or individual condition.

The pharmaceutical preparation will be supplied in the form of suitable dosage unit form, e.g., a capsule or tablet, and comprising an amount, being together with the further component(s) jointly effective.

The doses of renin inhibitor of formula (I) to be administered to warm-blooded animals, e.g., human beings; of, e.g., approximately 70 kg body weight, especially the doses effective in the inhibition of the enzyme renin, e.g., in lowering blood pressure and/or in improving the symptoms of glaucoma, are from approximately 3 mg to approximately 3 g, preferably from approximately 10 mg to approximately 1 g, e.g., approximately from 20-200 mg/person/day, divided preferably into 1-4 single doses which may, e.g., be of the same size. Usually, children receive about half of the adult dose. The dose necessary for each individual can be monitored, e.g., by measuring the serum concentration of the active ingredient, and adjusted to an optimum level. Single doses comprise, e.g., 75 mg, 150 mg or 300 mg per adult patient.

Valsartan, as a representative of the class of AT<sub>1</sub>-receptor antagonists, will be supplied in the form of suitable dosage unit form, e.g., a capsule or tablet, and comprising a therapeutically effective amount, e.g., from about 20 mg to about 320 mg, of valsartan which may be applied to patients. The application of the active ingredient may occur up to three times a day (t.i.d.), starting, e.g., with a daily dose of 20 mg or 40 mg of valsartan, increasing via 80 mg daily and further to 160 mg daily up to 320 mg daily. Preferably, valsartan is applied twice a day (b.i.d.) with a dose of 80 mg or 160 mg, respectively, each. Corresponding doses may be taken, e.g., in the morning, at mid-day or in the evening. Preferred is b.i.d. administration.

In case of HMG-Co-A reductase inhibitors, preferred dosage unit forms of HMG-Co-A reductase inhibitors are, e.g., tablets or capsules comprising, e.g., from about 5 mg to about 120 mg, preferably, when using fluvastatin, e.g., 20 mg, 40 mg or 80 mg (equivalent to the free acid) of fluvastatin, e.g., administered once a day.


In case of ACE inhibitors, preferred dosage unit forms of ACE inhibitors are, e.g., tablets or capsules comprising, e.g., from about 5 mg to about 20 mg, preferably 5 mg, 10 mg, 20 mg or 40 mg of benazepril; from about 6.5-100 mg, preferably 6.25 mg, 12.5 mg, 25 mg, 50 mg, 75 mg or 100 mg of captopril; from about 2.5 mg to about 20 mg, preferably 2.5 mg, 5 mg, 10 mg or 20 mg of enalapril; from about 10 mg to about 20 mg, preferably 10 mg or 20 mg of fosinopril; from about 2.5 mg to about 4 mg, preferably 2 mg or 4 mg of perindopril; from about 5 mg to about 20 mg, preferably 5 mg, 10 mg or 20 mg of quinapril; or from about 1.25 mg to about 5 mg, preferably 1.25 mg, 2.5 mg, or 5 mg of ramipril. Preferred is t.i.d. administration.

For example, suitable daily dosages of beta-blockers for adults of the following compounds for oral administration are as indicated: acebutol — 200-1200 mg; atenolol — 25-100 mg; betaxolol — 10-20 mg; bisoprolol — 5-10 mg; carteolol — 2.5-10 mg; labetalol — 100-1800 mg; metoprolol — 50-450 mg; nadolol — 40-240 mg; oxprenol — 60-480 mg; penbutolol — 20-80 mg; pindolol — 10-60 mg; propranolol — 40-320 mg or 60-320 mg for long-acting formulation); sotalol — 160-320 mg; timolol — 20-60 mg. Especially preferred beta-blockers for use in the present invention are atenolol, metoprolol and propranolol.

Especially preferred are low-dose combinations.


We Claim:

1. A method for the prevention of, delay progression to or treatment of a condition or disease selected from diabetes type 2 (associated with or without hypertension), severe hypertension, pulmonary hypertension (PH), malignant hypertension, isolated systolic hypertension, familial dyslipidemic hypertension, endothelial dysfunction (with or without hypertension), survival post-myocardial infarction (MI), increase of formation of collagen and other extracellular matrix proteins, restenosis after stenting, peripheral vascular disease (PWD) including peripheral artery disease (PAD) and peripheral venous disorders, coronary arterial disease (CAD), morbidity, mortality, cerebrovascular diseases, metabolic disorder (Syndrome X), atrial fibrillation (AF), renoprotection, reduction of proteinuria, renal failure, glomerulonephritis, nephrotic syndrome, renal fibrosis, acute interstitial nephritis (AIN), acute tubular nephritis (ATN), acute tubulo-interstitial nephritis, polycystic kidney disease (PKD), vascular inflammation, renin secreting tumors, vasculitides or closure, restenosis of dialysis access grafts, comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof.
2. A method of aiding plaque stabilization comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof.
3. The method of Claim 1, wherein the renin inhibitor is a compound of formula (I)



or a pharmaceutically acceptable salt thereof.

4. The method of Claim 2, wherein the renin Inhibitor is a compound of formula (I)



or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising a renin inhibitor in combination and at least one additional active agent selected from the group consisting of:

- (i) an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof;
- (ii) ACE inhibitor or a pharmaceutically acceptable salt thereof;
- (iii) calcium channel blocker or a pharmaceutically acceptable salt thereof;
- (iv) HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof;
- (v) aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof;
- (vi) aldosterone antagonist or a pharmaceutically acceptable salt thereof;
- (vii) dual ACE/NEP inhibitor or a pharmaceutically acceptable salt thereof;
- (viii) beta-blocker or a pharmaceutically acceptable salt thereof;
- (ix) endothelin antagonist or a pharmaceutically acceptable salt thereof;
- (x) diuretic or a pharmaceutically acceptable salt thereof;
- (xi) oral hypoglycaemic agent or a pharmaceutically acceptable salt thereof;
- (xii) Mrp2 inhibitor;
- (xiii) furosemide or a pharmaceutically acceptable salt thereof; and
- (xiv) Gleevec or a pharmaceutically acceptable salt thereof.

6. The pharmaceutical composition of Claim 5, wherein the rennin inhibitor is a compound of formula (I) or a pharmaceutically acceptable salt thereof.

7. A method for the prevention of, delay progression to overt to or treatment of a condition or disease selected from:

- (a) diabetes type 2 (associated with or without hypertension);


- (b) severe hypertension, PH, malignant hypertension, isolated systolic hypertension and familial dyslipidemic hypertension;
- (c) endothelial dysfunction (with or without hypertension);
- (d) survival post-MI, increase of formation of collagen and coarctation of aorta;
- (e) restenosis after percutaneous transluminal angioplasty
- (f) PVD, including PAD and peripheral venous disorders;
- (g) CAD;
- (h) morbidity and mortality;
- (i) cerebrovascular diseases;
- (j) metabolic disorder (Syndrome X);
- (k) AF;
- (l) organ protection;
- (m) renoprotection;
- (n) renal failure, e.g., chronic renal failure;
- (o) glomerulonephritis (may be associated with the nephritic syndrome, a high blood pressure and a decreased renal function), focal, segmental glomerulonephritis and minimal change nephropathy;
- (p) nephrotic syndrome and renal fibrosis;
- (q) AIN, ATN and acute tubulo-interstitial nephritis;
- (r) end-stage renal disease (ESRD);
- (s) PKD;
- (t) vascular inflammation;
- (u) obesity;
- (v) migraine headaches
- (w) renin secreting tumors; and
- (x) vasculitides,

comprising administering to a warm-blooded animal an effective amount of the pharmaceutical composition of Claim 5.

8. The method of Claim 7, wherein the rennin inhibitor is a compound of formula (I) or a pharmaceutically acceptable salt thereof.

9. A method of aiding plaque stabilization comprising administering to a warm-blooded animal an effective amount of the pharmaceutical composition of Claim 5.

10. The method of Claim 9, wherein the renin inhibitor is a compound of formula (I)



or a pharmaceutically acceptable salt thereof.

Abstract of the Disclosure

The present is directed to a method for the prevention of, delay progression to or treatment of a condition or disease selected from diabetes type 2 (associated with or without hypertension), severe hypertension, PH, malignant hypertension, isolated systolic hypertension, familial dyslipidemic hypertension, endothelial dysfunction (with or without hypertension), survival post-MI, increase of formation of collagen and other extracellular matrix proteins, restenosis after stenting, PVD including PAD and peripheral venous disorders; CAD, morbidity, mortality, cerebrovascular diseases, metabolic disorder (Syndrome X), AF, renoprotection, reduction of proteinuria, renal failure, glomerulonephritis, nephrotic syndrome, renal fibrosis, AIN, ATN, acute tubulo-interstitial nephritis, PKD, vascular inflammation, rennin secreting tumors, vasculitides or closure, restenosis of dialysis access grafts comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof alone or in combination with another active ingredient.

**INTERNATIONAL SEARCH REPORT**

International Application No  
PCT/EP2005/002809

A. CLASSIFICATION OF SUBJECT MATTER				
A61K31/00	A61K31/165	A61K45/06	A61P3/10	A61P9/12
A61P9/10	A61P13/12	A61P9/00	A61P39/00	A61P3/04
A61P25/06	A61P35/00			

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, MEDLINE, EMBASE, SCISEARCH, CANCERLIT BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 02/40007 A (NOVARTIS AG; NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H; HEWIT) 23 May 2002 (2002-05-23)</p> <p>page 1, paragraph 1 – page 2, paragraph 1 page 2, paragraph 4 – page 3, last paragraph page 7, paragraphs 2,3 page 8, paragraph 2 page 9, paragraph 2 page 15, paragraph 4 page 16, paragraph 2 – page 17, paragraph 1 page 19, paragraph 2 examples 1-11,16 claims 1,3-5,8-10</p> <p>-----</p> <p style="text-align: center;">-/--</p>	1,3,5-10

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the International filing date but later than the priority date claimed

- \*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

24 January 2006

Date of mailing of the International search report

21/02/2006

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Cielen, E

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2005/002809

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2003/114389 A1 (WEBB RANDY LEE) 19 June 2003 (2003-06-19) page 1, paragraphs 1-3,5 page 3, paragraphs 30,31,37-39 page 4, paragraphs 42,46 page 5, paragraph 59 claims 1,2,6	1,3
X	WO 01/15673 A (AVENTIS PHARMA DEUTSCHLAND GMBH) 8 March 2001 (2001-03-08)	1
Y	page 1, lines 6-12 page 3, lines 30-32 page 5, lines 1-3 page 5, line 10 page 7, line 29 – page 8, line 9 claims 3,12	3
X	EP 1 312 379 A (TAKEDA CHEMICAL INDUSTRIES, LTD) 21 May 2003 (2003-05-21) page 2, paragraph 1 pages 16-17, paragraph 88 page 17, paragraphs 89,90,92 page 18, paragraph 103 claims 11,12,26,27	1,3
X	WO 03/099279 A (NOVARTIS AG; NOVARTIS PHARMA GMBH; HOLMES, DAVID, GRENVILLE; SHETTY, S) 4 December 2003 (2003-12-04) page 1, paragraphs 1,2 page 7, paragraph 3 – page 8, paragraph 3 page 11, paragraph 5 page 12, paragraph 5 page 14, paragraph 5 – page 15, paragraph 1 page 19, paragraph 1 page 20, paragraph 4 – page 21, paragraph 1 page 26, paragraph 4 claims 1,2,4-6,10	1,3
X	US 5 376 638 A (YOUNG ET AL) 27 December 1994 (1994-12-27) column 1, lines 6-12 column 9, lines 14-19 column 12, lines 36-40 claim 6	1
	-/-	

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2005/002809

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2004/002549 A (NOVARTIS AG; NOVARTIS PHARMA GMBH; PRESCOTT, MARGARET, FORNEY) 8 January 2004 (2004-01-08)	5-10
A	page 1, paragraph 1 page 5, paragraph 5 page 6, paragraph 3 - page 8, paragraph 1 page 8, last paragraph - page 10, paragraph 8 page 17, paragraph 2-5 page 18, paragraph 2 - page 19, paragraph 4 page 27, paragraph 4 - page 28, paragraph 1 claims 1-5, 7-10, 12, 24, 27-29, 31 -----	1
E	WO 2005/070406 A (NOVARTIS AG; NOVARTIS PHARMA GMBH; FELDMAN, DAVID, LOUIS) 4 August 2005 (2005-08-04)	1, 3
	page 1, paragraph 1 - page 2, paragraph 1 page 8, paragraph 1 page 9, paragraph 7 - page 10, paragraph 1 page 11, paragraph 3 page 11, paragraph 7 - page 12, paragraph 3 page 13, paragraph 5 - page 14, paragraph 2 claims 1, 3, 4, 8 -----	
X	EP 0 573 652 A (FUJISAWA PHARMACEUTICAL CO., LTD) 15 December 1993 (1993-12-15)	1
Y	page 2, line 3 - page 3, line 4 claim 1 -----	3
X	US 5 182 266 A (KLEINERT ET AL) 26 January 1993 (1993-01-26)	1
Y	column 1, lines 10-49 column 1, line 68 - column 4, line 27 column 45, lines 21-44 claims 1, 2 -----	3
X	EP 0 518 676 A (MERCK & CO. INC) 16 December 1992 (1992-12-16)	1
	page 2, lines 5-10 page 3, line 16 - page 7, line 9 page 64, lines 45-53 page 65, line 5 -----	
	-/-	

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2005/002809

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ALLIKMETS KRISTINA: "Aliskiren (Speedel)." CURRENT OPINION IN INVESTIGATIONAL DRUGS (LONDON, ENGLAND : 2000), (2002 OCT) 3 (10) 1479-82. REF: 27 JOURNAL CODE: 100965718. ISSN: 1472-4472., October 2002 (2002-10), XP009017210 abstract	1,3
Y	page 1479, column 1, last paragraph page 1480, column 1, paragraph 4 page 1480, column 2, paragraphs 2,3	3,6,8,10
X	MAIBAUM J. ET AL: "Renin inhibitors as novel treatments for cardiovascular disease." EXPERT OPINION ON THERAPEUTIC PATENTS, (1 MAY 2003) VOL. 13, NO. 5, PP. 589-603. REFS: 96 ISSN: 1354-3776 CODEN: EOTPEG, 1 May 2003 (2003-05-01), XP002327881 page 594, column 1, paragraph 3 page 596, column 2, paragraph 1 page 598, column 1, paragraphs 2,3 page 598, column 1, last paragraph page 598, column 2, paragraph 3-5	1,5-8
P,X	WO 2004/100871 A (PHARMACIA CORPORATION; MCMAHON, ELLEN, G; RUDOLPH, AMY, E) 25 November 2004 (2004-11-25) page 1, lines 5-9 page 2, lines 4-23 page 8, line 1 - page 10, line 19 page 17, lines 31-33 page 34, lines 7-17 page 35, lines 1-28 table 2 page 45, line 14 - page 46, line 12 page 57, line 6 - page 59, line 28 page 59, lines 33-35 page 60, lines 19-21 claims 1,5,6,10,11,14	1,3,5-10
E	WO 2005/054244 A (ACTELION PHARMACEUTICALS LTD; BEZENCON, OLIVIER; SIFFERLEN, THIERRY; B) 16 June 2005 (2005-06-16) page 2, line 25 - page 5, line 7 page 11, line 31 - page 12, line 8 claims 1,14	1
		-/-

**INTERNATIONAL SEARCH REPORT**

International Application No  
PCT/EP2005/002809

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92/10097 A (SMITHKLINE BEECHAM CORPORATION) 25 June 1992 (1992-06-25) page 1, lines 17-26 page 19, lines 8-26 page 28, lines 13-17 page 28, lines 25-32 examples 16-18 claims 22-28, 57-63	5,7
Y	US 5 821 232 A (FOSSA ET AL) 13 October 1998 (1998-10-13) column 1, lines 15-25 column 3, lines 2-18 column 4, lines 45-65 claims 1,4-6,9	6,8
X	WO 03/035046 A (NOVARTIS AG; NOVARTIS PHARMA GMBH; BUEHLMAYER, PETER; WEBB, RANDY, LEE) 1 May 2003 (2003-05-01) page 1, paragraph 1 page 4, paragraph 3 page 4, last paragraph - page 5, paragraph 1 page 8, paragraph 3-5 pages 12-14; examples 1,2 pages 15-16; examples 1,2 claims 1-5,11,12	5-10
X	WO 03/099767 A (NOVARTIS AG; NOVARTIS PHARMA GMBH; ALLMENDINGER, THOMAS; FURTER, PETER) 4 December 2003 (2003-12-04) page 1, paragraph 1 page 3, paragraph 5 page 6, paragraph 1 page 13, paragraph 1 page 13, paragraph 4 - page 14, last paragraph page 17, paragraph 5 claims 1,5,7	5,7,9
Y		6,8,10
A	M.H. BEERS, R. BERKOW: "The Merck Manual of Diagnosis and Therapy, Seventeenth Edition" 1999, MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION, N.J. , XP002364176 page 1655, column 1, paragraph 5 page 1656, column 1, paragraph 3	9,10
	-/-	

## INTERNATIONAL SEARCH REPORT

International Application No PCT/EP2005/002809
---

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FOSSA ANTHONY A ET AL: "Synergistic Effect on Reduction in Blood Pressure With Coadministration of a Renin Inhibitor or an Angiotensin-Converting Enzyme Inhibitor With an Angiotensin II Receptor Antagonist" DRUG DEVELOPMENT RESEARCH, vol. 33, no. 4, 1994, pages 422-428, XP008058617 ISSN: 0272-4391 abstract page 424, column 2, paragraphs 2,3 figure 1 page 426, column 1, paragraph 2	5,7
Y		6,8
X	US 2003/229007 A1 (LEVI ROBERTO ET AL) 11 December 2003 (2003-12-11) page 1, paragraphs 11,16 pages 2-3, paragraph 26-29 page 3, paragraph 34 claims 1-3,5,7-9	5-8
X	US 5 202 322 A (ALLEN ET AL) 13 April 1993 (1993-04-13) column 1, lines 6-39 column 24, lines 20-38 column 25, lines 9-35 claims 8,9	5,7,9
Y		6,8,10
X	WO 2004/002957 A (ACTELION PHARMACEUTICALS LTD; BEZENCON, OLIVIER; BUR, DANIEL; FISCHLI,) 8 January 2004 (2004-01-08) page 1, lines 5-12 page 3, line 9 - page 4, line 22 page 24, lines 19-29 page 25, lines 17-22 claims 1,7,10	1,5,7,9
Y		3,6,8,10
	-/-	

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2005/002809

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>AZIZI MICHEL ET AL: "Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption"  JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY,  vol. 15, no. 12, December 2004 (2004-12),  pages 3126-3133, 3117, XP008058615  ISSN: 1046-6673  abstract  page 3126, column 2, paragraph 2 - page  3127, column 1, paragraph 1  page 3129, column 2, last paragraph - page  3130, column 1, paragraph 1  page 3132, column 1, last paragraph -  column 2, paragraph 2</p>	5-8
X	US 4 885 292 A (RYONO ET AL) 5 December 1989 (1989-12-05)	5,7
Y	column 2, line 19 - column 5, line 43 column 16, lines 1-19 example 49	6,8
X	WO 03/097098 A (NOVARTIS AG; NOVARTIS PHARMA GMBH; FELDMAN, DAVID, LOUIS; WEBB, RANDY,) 27 November 2003 (2003-11-27) page 3, paragraphs 3,4 page 4, paragraph 3 page 4, last paragraph - page 5, paragraph 1 page 6, last paragraph - page 7, paragraph 1 page 7, paragraph 4 - page 8, paragraph 1 page 8, paragraph 3 page 8, last paragraph - page 9, paragraph 1 page 13, last paragraph - page 14, paragraph 1 page 16, paragraph 1-3 claims 1-3,6	1,3,5-10
	-/-	

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2005/002809

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BOGER ROBERT S ET AL: "Dose-dependent effects on blood pressure and the renin-angiotensin system with a new orally active renin inhibitor (A-72517) in diuretic-pretreated normal volunteers" CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 53, no. 2, 1993, page 140, XP008058673 & NINETY-FOURTH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS; HONOLULU, HAWAII, USA; MARCH 24-26, 1993 ISSN: 0009-9236 the whole document	5,7
Y		6,8
X	HIMMELMANN ANDERS ET AL: "Remikiren (RO 42-5892): An orally active renin inhibitor in essential hypertension: Effects on blood pressure and the renin-angiotensin-aldosterone system" AMERICAN JOURNAL OF HYPERTENSION, vol. 9, no. 6, 1996, pages 517-522, XP002327883 ISSN: 0895-7061 abstract page 520, column 1, paragraph 3 page 521, column 1, last paragraph	5,7
Y		6,8
X	WO 01/15674 A (AVENTIS PHARMA DEUTSCHLAND GMBH) 8 March 2001 (2001-03-08) page 1, lines 6-15 page 3, lines 6-22 page 6, lines 6-9 page 8, lines 23-26 page 13, lines 29-33 claims 1,5-7	5,7
E	WO 2005/077418 A (NOVARTIS AG; NOVARTIS PHARMA GMBH; SHETTY, SURAJ, SHIVAPPA) 25 August 2005 (2005-08-25) page 1, paragraph 1 - page 2, paragraph 5 page 3, paragraph 5 page 12, paragraph 2; claims 1-3,5	5-10
E	WO 2005/023183 A (NITROMED, INC; GARVEY, DAVID, S; LETTS, L., GORDON; WORCEL, MANUEL; EA) 17 March 2005 (2005-03-17) page 1, lines 9-21 page 2, line 26 - page 3, line 12 page 5, line 17 - page 6, line 5 page 6, line 28 - page 7, line 4 page 9, lines 9,10 page 51, line 31 - page 52, line 12 page 67, line 25 - page 68, line 12 page 70, line 21 - page 73, line 10	5-10

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2005/002809

### Box II Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 1, 3 and 7-10 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box III Observations where unity of invention is lacking (Continuation of Item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  
**1, 3, 5-10 (all partially)**
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1, 3 (all partially)

A method for the prevention of, delay progression to or treatment of a condition or disease selected from diabetes type 2 (associated with or without hypertension) or metabolic disorder (Syndrome X), comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof, wherein the renin inhibitor is not combined with at least one additional active agent as defined in inventions 17-29.

2. claims: 1, 3 (all partially)

A method for the prevention of, delay progression to or treatment of a condition or disease selected from severe hypertension, pulmonary hypertension (PH), malignant hypertension, isolated systolic hypertension or familial dyslipidemic hypertension, comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof, wherein the renin inhibitor is not combined with at least one additional active agent as defined in inventions 17-29.

3. claims: 1, 3 (all partially)

A method for the prevention of, delay progression to or treatment of endothelial dysfunction (with or without hypertension), comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof, wherein the renin inhibitor is not combined with at least one additional active agent as defined in inventions 17-29.

4. claims: 1, 3 (all partially)

A method for the prevention of, delay progression to or treatment of survival post-myocardial infarction (MI), comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof, wherein the renin inhibitor is not combined with at least one additional active agent as defined in inventions 17-29.

5. claims: 1, 3 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A method for the prevention of, delay progression to or treatment of increase of formation of collagen and other extracellular matrix proteins, comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof, wherein the renin inhibitor is not combined with at least one additional active agent as defined in inventions 17-29.

---

6. claims: 1, 3 (all partially)

A method for the prevention of, delay progression to or treatment of a condition or disease selected from restenosis after stenting or restenosis of dialysis access grafts, comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof, wherein the renin inhibitor is not combined with at least one additional active agent as defined in inventions 17-29.

---

7. claims: 1, 3 (all partially)

A method for the prevention of, delay progression to or treatment of peripheral vascular disease (PWD), including peripheral artery disease (PAD) and peripheral venous disorders, comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof, wherein the renin inhibitor is not combined with at least one additional active agent as defined in inventions 17-29.

---

8. claims: 1, 3 (all partially)

A method for the prevention of, delay progression to or treatment of coronary arterial disease (CAD), comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof, wherein the renin inhibitor is not combined with at least one additional active agent as defined in inventions 17-29.

---

9. claims: 1, 3 (all partially)

A method for the prevention of, delay progression to or treatment of a condition or disease selected from morbidity or mortality, comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof, wherein the renin inhibitor is not combined with at least one additional active agent as defined in inventions 17-29.

---

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

10. claims: 1, 3 (all partially)

A method for the prevention of, delay progression to or treatment of cerebrovascular diseases, comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof, wherein the renin inhibitor is not combined with at least one additional active agent as defined in inventions 17-29.

11. claims: 1, 3 (all partially)

A method for the prevention of, delay progression to or treatment of atrial fibrillation (AF), comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof, wherein the renin inhibitor is not combined with at least one additional active agent as defined in inventions 17-29.

12. claims: 1, 3 (all partially)

A method for the prevention of, delay progression to or treatment of a condition or disease selected from renoprotection, reduction of proteinuria, renal failure, glomerulonephritis, nephrotic syndrome, renal fibrosis, acute interstitial nephritis (AIN), acute tubular nephritis (ATN), acute tubulo-interstitial nephritis or polycystic kidney disease (PKD), comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof, wherein the renin inhibitor is not combined with at least one additional active agent as defined in inventions 17-29.

13. claims: 1, 3 (all partially)

A method for the prevention of, delay progression to or treatment of vascular inflammation, comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof, wherein the renin inhibitor is not combined with at least one additional active agent as defined in inventions 17-29.

14. claims: 1, 3 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A method for the prevention of, delay progression to or treatment of renin secreting tumors, comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof, wherein the renin inhibitor is not combined with at least one additional active agent as defined in inventions 17-29.

15. claims: 1, 3 (all partially)

A method for the prevention of, delay progression to or treatment of vasculitides or closure, comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof, wherein the renin inhibitor is not combined with at least one additional active agent as defined in inventions 17-29.

16. claims: 2, 4 (all entirely)

A method of aiding plaque stabilisation, comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof, wherein the renin inhibitor is not combined with at least one additional active agent as defined in inventions 17-29.

17. claims: 5-10 (all partially)

A pharmaceutical composition comprising a renin inhibitor in combination with at least one additional active agent which is an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof.  
A method for the prevention of, delay progression to overt or treatment of a condition or disease as defined under (a) to (x) in claim 7 or for aiding plaque stabilisation as defined in claim 9, comprising administering to a warm-blooded animal an effective amount of such a pharmaceutical composition.

18. claims: 5-10 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A pharmaceutical composition comprising a renin inhibitor in combination with at least one additional active agent which is an ACE inhibitor or a pharmaceutically acceptable salt thereof.

A method for the prevention of, delay progression to overt or treatment of a condition or disease as defined under (a) to (x) in claim 7 or for aiding plaque stabilisation as defined in claim 9, comprising administering to a warm-blooded animal an effective amount of such a pharmaceutical composition.

19. claims: 5-10 (all partially)

A pharmaceutical composition comprising a renin inhibitor in combination with at least one additional active agent which is CCB or a pharmaceutically acceptable salt thereof.

A method for the prevention of, delay progression to overt or treatment of a condition or disease as defined under (a) to (x) in claim 7 or for aiding plaque stabilisation as defined in claim 9, comprising administering to a warm-blooded animal an effective amount of such a pharmaceutical composition.

20. claims: 5-10 (all partially)

A pharmaceutical composition comprising a renin inhibitor in combination with at least one additional active agent which is a HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof.

A method for the prevention of, delay progression to overt or treatment of a condition or disease as defined under (a) to (x) in claim 7 or for aiding plaque stabilisation as defined in claim 9, comprising administering to a warm-blooded animal an effective amount of such a pharmaceutical composition.

21. claims: 5-10 (all partially)

A pharmaceutical composition comprising a renin inhibitor in combination with at least one additional active agent which is an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof.

A method for the prevention of, delay progression to overt or treatment of a condition or disease as defined under (a) to (x) in claim 7 or for aiding plaque stabilisation as defined in claim 9, comprising administering to a warm-blooded animal an effective amount of such a pharmaceutical composition.

22. claims: 5-10 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A pharmaceutical composition comprising a renin inhibitor in combination with at least one additional active agent which is an aldosterone antagonist or a pharmaceutically acceptable salt thereof.

A method for the prevention of, delay progression to overt or treatment of a condition or disease as defined under (a) to (x) in claim 7 or for aiding plaque stabilisation as defined in claim 9, comprising administering to a warm-blooded animal an effective amount of such a pharmaceutical composition.

23. claims: 5-10 (all partially)

A pharmaceutical composition comprising a renin inhibitor in combination with at least one additional active agent which is a dual ACE/NEP inhibitor or a pharmaceutically acceptable salt thereof.

A method for the prevention of, delay progression to overt or treatment of a condition or disease as defined under (a) to (x) in claim 7 or for aiding plaque stabilisation as defined in claim 9, comprising administering to a warm-blooded animal an effective amount of such a pharmaceutical composition.

24. claims: 5-10 (all partially)

A pharmaceutical composition comprising a renin inhibitor in combination with at least one additional active agent which is a beta-blocker or a pharmaceutically acceptable salt thereof.

A method for the prevention of, delay progression to overt or treatment of a condition or disease as defined under (a) to (x) in claim 7 or for aiding plaque stabilisation as defined in claim 9, comprising administering to a warm-blooded animal an effective amount of such a pharmaceutical composition.

25. claims: 5-10 (all partially)

A pharmaceutical composition comprising a renin inhibitor in combination with at least one additional active agent which is an endothelin antagonist or a pharmaceutically acceptable salt thereof.

A method for the prevention of, delay progression to overt or treatment of a condition or disease as defined under (a) to (x) in claim 7 or for aiding plaque stabilisation as defined in claim 9, comprising administering to a warm-blooded animal an effective amount of such a pharmaceutical composition.

26. claims: 5-10 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A pharmaceutical composition comprising a renin inhibitor in combination with at least one additional active agent which is a diuretic or furosemide or a pharmaceutically acceptable salt thereof.

A method for the prevention of, delay progression to overt or treatment of a condition or disease as defined under (a) to (x) in claim 7 or for aiding plaque stabilisation as defined in claim 9, comprising administering to a warm-blooded animal an effective amount of such a pharmaceutical composition.

---

27. claims: 5-10 (all partially)

A pharmaceutical composition comprising a renin inhibitor in combination with at least one additional active agent which is an oral hypoglycaemic agent or a pharmaceutically acceptable salt thereof.

A method for the prevention of, delay progression to overt or treatment of a condition or disease as defined under (a) to (x) in claim 7 or for aiding plaque stabilisation as defined in claim 9, comprising administering to a warm-blooded animal an effective amount of such a pharmaceutical composition.

---

28. claims: 5-10 (all partially)

A pharmaceutical composition comprising a renin inhibitor in combination with at least one additional active agent which is a Mrp2 inhibitor or a pharmaceutically acceptable salt thereof.

A method for the prevention of, delay progression to overt or treatment of a condition or disease as defined under (a) to (x) in claim 7 or for aiding plaque stabilisation as defined in claim 9, comprising administering to a warm-blooded animal an effective amount of such a pharmaceutical composition.

---

29. claims: 5-10 (all partially)

A pharmaceutical composition comprising a renin inhibitor in combination with at least one additional active agent which is Gleevec or a pharmaceutically acceptable salt thereof.

A method for the prevention of, delay progression to overt or treatment of a condition or disease as defined under (a) to (x) in claim 7 or for aiding plaque stabilisation as defined in claim 9, comprising administering to a warm-blooded animal an effective amount of such a pharmaceutical composition.

---

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/EP2005/002809

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 0240007	A 23-05-2002	AU 2368002 A		27-05-2002
		BR 0115411 A		17-08-2004
		CA 2428647 A1		23-05-2002
		CN 1474690 A		11-02-2004
		EP 1341533 A1		10-09-2003
		HU 0301841 A2		29-09-2003
		JP 2004513920 T		13-05-2004
		MX PA03004358 A		19-08-2003
		NO 20032233 A		16-05-2003
		NZ 525795 A		24-03-2005
		PL 361404 A1		04-10-2004
		SK 5842003 A3		04-11-2003
		ZA 200303497 A		28-04-2004
US 2003114389	A1 19-06-2003	NONE		
WO 0115673	A 08-03-2001	AT 307604 T		15-11-2005
		AU 7648400 A		26-03-2001
		BG 106319 A		29-12-2002
		BR 0013540 A		30-04-2002
		CA 2382387 A1		08-03-2001
		CN 1384756 A		11-12-2002
		CZ 20020644 A3		15-05-2002
		DE 60023518 D1		01-12-2005
		EE 200200085 A		15-04-2003
		EP 1212081 A2		12-06-2002
		HR 20020169 A2		31-10-2005
		HU 0202461 A2		28-12-2002
		JP 2003508426 T		04-03-2003
		MX PA02001633 A		06-08-2002
		NO 20020850 A		21-02-2002
		PL 353066 A1		06-10-2003
		SK 2702002 A3		10-09-2002
		TR 200200518 T2		21-06-2002
		TR 200202463 T2		21-01-2003
		TR 200202464 T2		21-01-2003
		TR 200202466 T2		23-12-2002
		TR 200202467 T2		23-12-2002
		ZA 200201471 A		03-03-2003
EP 1312379	A 21-05-2003	AU 8013501 A		04-03-2002
		CA 2420055 A1		31-01-2003
		WO 0215935 A1		28-02-2002
		US 2003187038 A1		02-10-2003
WO 03099279	A 04-12-2003	AU 2003242593 A1		12-12-2003
		BR 0311397 A		15-03-2005
		CA 2487167 A1		04-12-2003
		CN 1655786 A		17-08-2005
		EP 1511484 A1		09-03-2005
		JP 2005532330 T		27-10-2005
US 5376638	A 27-12-1994	AU 5099193 A		29-03-1994
		CA 2143653 A1		17-03-1994
		EP 0661991 A1		12-07-1995
		JP 8501296 T		13-02-1996
		WO 9405317 A1		17-03-1994

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/EP2005/002809

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 2004002549	A	08-01-2004	AU 2003250858 A1 CA 2490811 A1 EP 1531879 A1 JP 2005537822 T		19-01-2004 08-01-2004 25-05-2005 15-12-2005
WO 2005070406	A	04-08-2005	NONE		
EP 0573652	A	15-12-1993	AU 1337992 A CA 2105291 A1 WO 9215296 A1 MX 9200869 A1 ZA 9201381 A		06-10-1992 02-09-1992 17-09-1992 01-09-1992 25-11-1992
US 5182266	A	26-01-1993	NONE		
EP 0518676	A	16-12-1992	CA 2070983 A1 JP 6157481 A		12-12-1992 03-06-1994
WO 2004100871	A	25-11-2004	NONE		
WO 2005054244	A	16-06-2005	NONE		
WO 9210097	A	25-06-1992	AT 177634 T AU 656551 B2 AU 9178291 A CA 2098176 A1 DE 10399008 I1 DE 69131021 D1 DE 69131021 T2 DK 565634 T3 EP 0565634 A1 ES 2130170 T3 GR 3030293 T3 HK 1012209 A1 JP 3398379 B2 JP 6503834 T NL 300115 I1		15-04-1999 09-02-1995 08-07-1992 14-06-1992 31-07-2003 22-04-1999 12-08-1999 27-09-1999 20-10-1993 01-07-1999 30-09-1999 12-05-2000 21-04-2003 28-04-1994 01-05-2003
US 5821232	A	13-10-1998	US 5663188 A		02-09-1997
WO 03035046	A	01-05-2003	BR 0213357 A CA 2463758 A1 CN 1571668 A EP 1448190 A2 JP 2005509631 T		26-10-2004 01-05-2003 26-01-2005 25-08-2004 14-04-2005
WO 03099767	A	04-12-2003	AU 2003242592 A1 BR 0311306 A CA 2484935 A1 CN 1656058 A EP 1511719 A1 JP 2005527619 T US 2005234126 A1		12-12-2003 15-02-2005 04-12-2003 17-08-2005 09-03-2005 15-09-2005 20-10-2005
US 2003229007	A1	11-12-2003	NONE		
US 5202322	A	13-04-1993	NONE		

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No  
PCT/EP2005/002809

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 2004002957	A	08-01-2004	AU 2003229746 A1		19-01-2004
			BR 0312000 A		22-03-2005
			CA 2490138 A1		08-01-2004
			CN 1662498 A		31-08-2005
			JP 2005532371 T		27-10-2005
US 4885292	A	05-12-1989	NONE		
WO 03097098	A	27-11-2003	AU 2003240669 A1		02-12-2003
			BR 0310084 A		15-02-2005
			CA 2485081 A1		27-11-2003
			CN 1655819 A		17-08-2005
			EP 1507558 A1		23-02-2005
			JP 2005526850 T		08-09-2005
WO 0115674	A	08-03-2001	AT 303800 T		15-09-2005
			AU 7649100 A		26-03-2001
			BG 106360 A		31-10-2002
			BR 0013704 A		07-05-2002
			CA 2382549 A1		08-03-2001
			CN 1368881 A		11-09-2002
			CZ 20020770 A3		12-06-2002
			DE 60022525 D1		13-10-2005
			EE 200200086 A		15-04-2003
			EP 1216038 A2		26-06-2002
			HR 20020170 A2		31-10-2005
			HU 0203326 A2		28-02-2003
			JP 2003527325 T		16-09-2003
			MX PA02001694 A		06-08-2002
			NO 20020978 A		18-04-2002
			NZ 517468 A		27-02-2004
			NZ 530702 A		29-07-2005
			PL 353199 A1		03-11-2003
			SK 2692002 A3		02-07-2002
			TR 200200515 T2		21-11-2002
			ZA 200201470 A		21-08-2003
WO 2005077418	A	25-08-2005	NONE		
WO 2005023183	A	17-03-2005	WO 2005023182 A2		17-03-2005